How to manage BRCA mutation carriers?
BRCA mutation
breast cancer
ovarian cancer
prophylactic mastectomy
risk reducing surgery
Journal
Hormone molecular biology and clinical investigation
ISSN: 1868-1891
Titre abrégé: Horm Mol Biol Clin Investig
Pays: Germany
ID NLM: 101538885
Informations de publication
Date de publication:
27 May 2020
27 May 2020
Historique:
received:
09
11
2019
accepted:
31
03
2020
pubmed:
28
5
2020
medline:
2
7
2021
entrez:
28
5
2020
Statut:
epublish
Résumé
Inherited mutations in BRCA1 and BRCA2 genes increase the risk of development of cancer in organs especially in breast and ovary. Prevention and screening in BRCA mutation carriers are of high importance. Prophylactic surgeries are possible but are still insufficiently performed because they require surgical procedures in healthy patients. Guidelines for the management of BRCA mutations carriers must absolutely be part of the standard practice of all those involved in the management of these patients to increase the impact of the implementation of these preventive measures. There is no screening recommended for ovarian cancer. A risk-reducing bilateral salpingo-oophorectomy should be performed from age 35 to 40 years for BRCA1 mutation carriers and 40 to 45 years for BRCA2 mutation carriers. A screening for breast cancer should be performed annually from 30 years old by breast MRI and mammography. A risk-reducing bilateral mastectomy is recommended with nipple sparing mastectomy and immediate breast reconstruction from 30 years and before 40 years. A multidisciplinary care must be implemented for these patients with an important psychological support.
Identifiants
pubmed: 32459193
doi: 10.1515/hmbci-2019-0065
pii: hmbci-2019-0065
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
PubMed – NCBI. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. USA: PubMed – NCBI. Available from: https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/30207593 [Internet]. [cited 2019 Oct 9].
Lynch HT, Silva E, Snyder C, Lynch JF. Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes. Breast J 2008;14:3–13. https://doi.org/10.1111/j.1524-4741.2007.00515.x.
US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US preventive services task force recommendation statement. JAMA 2019;322:652–65. https://doi.org/10.1001/jama.2019.10987.
Paul A, Paul S. The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers. Front Biosci Landmark Ed 2014;19:605–18. https://doi.org/10.2741/4230.
King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643–6. https://doi.org/10.1126/science.1088759.
Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 2015;121:269–75. https://doi.org/10.1002/cncr.29041.
Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117–30. https://doi.org/10.1086/375033.
van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJE, de Vries J, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat 2010;124:643–51. https://doi.org/10.1007/s10549-010-0805-3.
Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol Off J Am Soc Clin Oncol 2007;25:1329–33. https://doi.org/10.1200/JCO.2006.09.1066.
Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017;317:2402–16. https://doi.org/10.1001/jama.2017.7112.
Kadouri L, Hubert A, Rotenberg Y, Hamburger T, Sagi M, Nechushtan C, et al. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. J Med Genet. 2007;44:467–71. https://doi.org/10.1136/jmg.2006.048173.
Evans DGR, Susnerwala I, Dawson J, Woodward E, Maher ER, Lalloo F. Risk of breast cancer in male BRCA2 carriers. J Med Genet 2010;47:710–1. https://doi.org/10.1136/jmg.2009.075176.
Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2007;99:1811–4. https://doi.org/10.1093/jnci/djm203.
Fathalla MF. Incessant ovulation--a factor in ovarian neoplasia?. Lancet Lond Engl 1971;2:163. https://doi.org/10.1016/s0140-6736(71)92335-x.
Murdoch WJ, Van Kirk EA, Alexander BM. DNA damages in ovarian surface epithelial cells of ovulatory hens. Exp Biol Med Maywood NJ 2005;230:429–33. https://doi.org/10.1177/15353702-0323006-11.
Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol Off J Am Soc Clin Oncol 2013;31:4188–98. https://doi.org/10.1200/JCO.2013.48.9021.
Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol 2008;27:1–9. https://doi.org/10.1097/pgp.0b013e31814b191f.
Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006;30:230–6. https://doi.org/10.1097/01.pas.0000180854.28831.77.
Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161–9. https://doi.org/10.1097/01.pas.0000213335.40358.47.
Poon C, Hyde S, Grant P, Newman M, Ireland Jenkin K. Incidence and characteristics of unsuspected neoplasia discovered in high-risk women undergoing risk reductive bilateral salpingooophorectomy. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 2016;26:1415–20. https://doi.org/10.1097/IGC.0000000000000791.
Ricciardi E, Tomao F, Aletti G, Bazzurini L, Bocciolone L, Boveri S, et al. Risk-reducing salpingo-oophorectomy in women at higher risk of ovarian and breast cancer: a single institution prospective series. Anticancer Res 2017;37:5241–8. https://doi.org/10.21873/anticanres.11948.
Hermsen BBJ, Olivier RI, Verheijen RHM, van Beurden M, de Hullu JA, Massuger LF, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 2007;96:1335–42. https://doi.org/10.1038/sj.bjc.6603725.
L'Institut National du Cancer (INCa). Femmes porteuses d'une mutation de BRCA1 ou BRCA2 /Détection précoce du cancer du sein et des annexes et stratégies de réduction du risque, Collection recommandations et référentiels. France: INCa, 2017 avril.
Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, et al. NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017. J Natl Compr Cancer Netw JNCCN 2017;15:9–20. https://doi.org/10.6004/jnccn.2017.0003.
Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:80–7. https://doi.org/10.1093/jnci/djn442.
Eleje GU, Eke AC, Ezebialu IU, Ikechebelu JI, Ugwu EO, Okonkwo OO. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. In: Cochrane gynaecological, Neuro-oncology and orphan cancer group, editors. Cochrane database systematic reviews; 2018. Available from: http://doi.wiley.com/10.1002/14651858.CD012464.pub2 [Internet] [cited 2019 Oct 31].
Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967–75. https://doi.org/10.1001/jama.2010.1237.
Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol. 2005;97:457–67. https://doi.org/10.1016/j.ygyno.2005.01.039.
Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609–15. https://doi.org/10.1056/NEJMoa020119.
Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616–22. https://doi.org/10.1056/NEJMoa012158.
Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Musio D, et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health. 2014;14:150. https://doi.org/10.1186/s12905-014-0150-5.
Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, et al. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol 2013;130:127–31. https://doi.org/10.1016/j.ygyno.2013.03.027.
Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, et al. Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol 2016;2:1434–40. https://doi.org/10.1001/jamaoncol.2016.1820.
Powell CB. Risk reducing salpingo-oophorectomy for BRCA mutation carriers: twenty years later. Gynecol Oncol 2014;132:261–3. https://doi.org/10.1016/j.ygyno.2014.01.018.
Ready K, Gutierrez-Barrera AM, Amos C, Meric-Bernstam F, Lu K, Hortobagyi G, et al. Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast J 2011;17:210–2. https://doi.org/10.1111/j.1524-4741.2010.01055.x.
Blok F, Roes EM, van Leenders GJLH, van Beekhuizen HJ. The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review. BMC Cancer 2016;16:18. https://doi.org/10.1186/s12885-015-2011-5.
Leblanc E, Narducci F, Farre I, Peyrat JP, Taieb S, Adenis C, et al. Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development. Gynecol Oncol 2011;121:472–6. https://doi.org/10.1016/j.ygyno.2011.02.012.
Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283:2260–5. https://doi.org/10.1001/jama.283.17.2260.
Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, et al. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol 2018;150:85–91. https://doi.org/10.1016/j.ygyno.2018.05.011.
Thompson D, Easton DF, Breast Cancer Linkage Consortium. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94:1358–65. https://doi.org/10.1093/jnci/94.18.1358.
Guidozzi F. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation. Climacteric J Int Menopause Soc 2016;19:419–22. https://doi.org/10.1080/13697137.2016.1209396.
Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch HT, Neuhausen SL, et al. Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. Breast Cancer Res Treat 2016;155:365–73. https://doi.org/10.1007/s10549-016-3685-3.
Hartmann LC, Lindor NM. The role of risk-reducing surgery in hereditary breast and ovarian cancer. N Engl J Med 2016;374:454–68. https://doi.org/10.1056/NEJMra1503523.
Bick U, Engel C, Krug B, Heindel W, Fallenberg EM, Rhiem K, Maintz D, et al. German consortium for hereditary breast and ovarian cancer (GC-HBOC). High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. Breast Cancer Res Treat 2019;175:217–28. https://doi.org/10.1007/s10549-019-05152-9.
Telli ML, Gradishar WJ, Ward JH. NCCN guidelines updates: breast cancer. J Natl Compr Cancer Netw JNCCN 2019;17:552–5. https://doi.org/10.6004/jnccn.2019.5006.
Milne RL, Osorio A, Cajal TRY, Vega A, Llort G, de la Hoya M, et al. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res Off J Am Assoc Cancer Res 2008;14:2861–9. https://doi.org/10.1158/1078-0432.CCR-07-4436.
Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol Off J Am Soc Clin Oncol 2006;24:863–71. https://doi.org/10.1200/JCO.2005.03.6772.
Heemskerk-Gerritsen BAM, Jager A, Koppert LB, Obdeijn AI-M, Collée M, Meijers-Heijboer HEJ, et al. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2019;177:723–33. https://doi.org/10.1007/s10549-019-05345-2.
De Felice F, Marchetti C, Musella A, Palaia I, Perniola G, Musio D, et al. Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Ann Surg Oncol 2015;22:2876–80. https://doi.org/10.1245/s10434-015-4532-1.
Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol Off J Am Soc Clin Oncol 2004;22:1055–62. https://doi.org/10.1200/JCO.2004.04.188.
Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:159–64. https://doi.org/10.1056/NEJM200107193450301.
Elder EE, Brandberg Y, Björklund T, Rylander R, Lagergren J, Jurell G, et al. Quality of life and patient satisfaction in breast cancer patients after immediate breast reconstruction: a prospective study. Breast Edinb Scotl 2005;14:201–8. https://doi.org/10.1016/j.breast.2004.10.008.
Eltahir Y, Werners LLCH, Dreise MM, van Emmichoven IAZ, Jansen L, Werker PMN, et al. Quality-of-life outcomes between mastectomy alone and breast reconstruction: comparison of patient-reported BREAST-Q and other health-related quality-of-life measures. Plast Reconstr Surg 2013;132:201e–9e. https://doi.org/10.1097/PRS.0b013e31829586a7.
Didier F, Radice D, Gandini S, Bedolis R, Rotmensz N, Maldifassi A, et al. Does nipple preservation in mastectomy improve satisfaction with cosmetic results, psychological adjustment, body image and sexuality?. Breast Cancer Res Treat 2009;118:623–33. https://doi.org/10.1007/s10549-008-0238-4.
Jakub JW, Peled AW, Gray RJ, Greenup RA, Kiluk JV, Sacchini V, et al. Oncologic safety of prophylactic nipple-sparing mastectomy in a population with BRCA mutations: a multi-institutional study. JAMA Surg 2018;153:123–9. https://doi.org/10.1001/jamasurg.2017.3422.
Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO clinical practice guidelines for cancer prevention and screening. Ann Oncol Off J Eur Soc Med Oncol 2016;27(5 Suppl):v103–10. https://doi.org/10.1093/annonc/mdw327.
Nkondjock A, Robidoux A, Paredes Y, Narod SA, Ghadirian P. Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. Breast Cancer Res Treat 2006;98:285–94. https://doi.org/10.1007/s10549-006-9161-8.
King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: national surgical adjuvant breast and bowel project (NSABP-P1) breast cancer prevention trial. JAMA 2001;286:2251–6. https://doi.org/10.1001/jama.286.18.2251.
Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer 2019;121:15–21. https://doi.org/10.1038/s41416-019-0446-1.
Forbes C, Fayter D, de Kock S, Quek RG. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer. Cancer Manag Res 2019;11:2321–37. https://doi.org/10.2147/CMAR.S189627.
Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, et al. Interim results from the impact study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol. 2019;76:831–42. https://doi.org/10.1016/j.eururo.2019.08.019.